肿瘤细胞治疗研究
英文原题：Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
我们的患者在接受 CAR T 细胞治疗后缓解期长达 4 年。
慢性淋巴细胞白血病（CLL）向弥漫性大B细胞淋巴瘤转化（DLBCL-RT）的患者预后极差。一名51岁女性患者于2009年诊断为伴del(17p)的CLL。CLL治疗包括化学免疫治疗和靶向药物。DLBCL-RT于2016年11月确诊。在接受异基因造血干细胞移植后，她于2019年9月复发，并于2019年12月输注tisagenlecleucel。2级细胞因子释放综合征接受两剂tocilizumab治疗，患者于2020年2月开始服用140 mg ibrutinib。我们的患者在CAR T细胞治疗后持续缓解达4年。
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation, she relapsed in September 2019 and tisagenlecleucel was infused in December 2019. Cytokine release syndrome grade 2 was treated with two doses of tocilizumab and the patient was started on 140 mg ibrutinib in February 2020. Our patient remains in remission up to 4 years after CAR T-cell treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
